The recent surge in funding into niche pharmaceutical companies, particularly those focusing on novel therapies and challenging drug development programs, has fueled what some are calling "High Investor Pharma." While the possibility for game-changing treatments and substantial returns is undeniable, the associated risks are also considerable. Many